Daily Cardiology Research Analysis
Three impactful cardiology studies stood out today: (1) a NEJM randomized trial showing that initial combination therapy with finerenone plus empagliflozin achieves substantially greater albuminuria reduction than either agent alone in chronic kidney disease with type 2 diabetes; (2) the ILUMIEN IV randomized trial demonstrating OCT-guided PCI lowers 2-year target-vessel failure in angiographically calcified lesions vs angiography guidance; and (3) an observational Stroke study associating GLP-1
Summary
Three impactful cardiology studies stood out today: (1) a NEJM randomized trial showing that initial combination therapy with finerenone plus empagliflozin achieves substantially greater albuminuria reduction than either agent alone in chronic kidney disease with type 2 diabetes; (2) the ILUMIEN IV randomized trial demonstrating OCT-guided PCI lowers 2-year target-vessel failure in angiographically calcified lesions vs angiography guidance; and (3) an observational Stroke study associating GLP-1 receptor agonists with lower risk of intracerebral hemorrhage in type 2 diabetes.
Research Themes
- Imaging-guided optimization of coronary PCI in calcified lesions
- Cardiorenal-metabolic combination therapy in CKD with T2D
- Cerebrovascular safety profiles of GLP-1 receptor agonists
Selected Articles
1. Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes.
In the CONFIDENCE RCT, initial combination therapy with finerenone plus empagliflozin achieved a 29–32% greater reduction in UACR at 180 days compared with either agent alone in CKD with T2D. Safety signals, including symptomatic hypotension, AKI, and hyperkalemia leading to discontinuation, were uncommon across groups.
Impact: This trial provides high-quality randomized evidence supporting early combination cardiorenal therapy, potentially redefining treatment sequencing in CKD with diabetes.
Clinical Implications: For patients with CKD and T2D, initiating finerenone plus an SGLT2 inhibitor may yield superior antiproteinuric effects versus monotherapy without new safety concerns, supporting earlier combination strategies alongside RAAS blockade.
Key Findings
- At day 180, combination therapy reduced UACR 29% more than finerenone alone (LS mean ratio 0.71; 95% CI 0.61–0.82; P<0.001).
- At day 180, combination therapy reduced UACR 32% more than empagliflozin alone (LS mean ratio 0.68; 95% CI 0.59–0.79; P<0.001).
- Symptomatic hypotension, acute kidney injury, and hyperkalemia leading to discontinuation were uncommon across all groups with no unexpected adverse events.
Methodological Strengths
- Randomized, parallel-group design with active comparators
- Clear primary endpoint (UACR change) with prespecified analyses and robust statistical significance
Limitations
- Primary endpoint is a surrogate (albuminuria) rather than hard cardiorenal outcomes
- Follow-up limited to 180 days; long-term efficacy and safety not assessed
Future Directions: Evaluate long-term cardiorenal outcomes, optimal sequencing vs upfront combination, and generalizability across CKD stages and diverse populations.
BACKGROUND: Limited evidence exists to support the simultaneous initiation of sodium-glucose cotransporter-2 inhibitors and finerenone, a nonsteroidal mineralocorticoid receptor antagonist, in persons with chronic kidney disease and type 2 diabetes. METHODS: We randomly assigned participants with chronic kidney disease (estimated glomerular filtration rate [eGFR], 30 to 90 ml per minute per 1.73 m RESULTS: At baseline, the urinary albumin-to-creatinine ratio was similar among the participants in the three groups; the median value was 579 (interquartile range, 292 to 1092) among those with available data (265 in the combination-therapy group, 258 in the finerenone group, and 261 participants in the empagliflozin group). At day 180, the reduction in the urinary albumin-to-creatinine ratio with combination therapy was 29% greater than that with finerenone alone (least-squares mean ratio of the difference in the change from baseline, 0.71; 95% confidence interval [CI], 0.61 to 0.82; P<0.001) and 32% greater than that with empagliflozin alone (least-squares mean ratio of the difference in the change from baseline, 0.68; 95% CI, 0.59 to 0.79; P<0.001). Neither agent, alone or in combination, led to unexpected adverse events. Symptomatic hypotension, acute kidney injury, and hyperkalemia leading to drug discontinuation were uncommon. CONCLUSIONS: Among persons with both chronic kidney disease and type 2 diabetes, initial therapy with finerenone plus empagliflozin led to a greater reduction in the urinary albumin-to-creatinine ratio than either treatment alone. (Funded by Bayer; CONFIDENCE ClinicalTrials.gov number, NCT05254002.).
2. Optical coherence tomography- vs angiography-guided coronary stent implantation in calcified lesions: the ILUMIEN IV trial.
Among patients with angiographically moderate/severe calcification, OCT-guided PCI achieved larger post-PCI minimal stent area and reduced 2-year target-vessel failure versus angiography guidance, driven by lower TV-MI and stent thrombosis. No benefit was observed in non/mildly calcified lesions.
Impact: This randomized evidence specifically in calcified lesions supports OCT-guided optimization to improve hard clinical outcomes, informing procedural strategy in a high-risk subset.
Clinical Implications: For angiographically moderate/severe calcification, OCT guidance should be strongly considered to optimize stent expansion and reduce TVF, TV-MI, and stent thrombosis, whereas routine OCT in non/mild calcification may be less impactful.
Key Findings
- In moderate/severe calcified lesions, post-PCI MSA was larger with OCT vs angiography guidance (5.57±1.86 mm² vs 5.33±1.78 mm²; P=0.03).
- Two-year TVF was lower with OCT guidance in calcified lesions (6.8% vs 9.7%; aHR 0.62; 95% CI 0.40–0.96).
- OCT guidance reduced TV-MI (1.9% vs 4.0%; aHR 0.36) and stent thrombosis (0.2% vs 1.5%; aHR 0.11) over 2 years in calcified lesions.
Methodological Strengths
- Randomized comparison with core-lab adjudication of calcification severity
- Prespecified clinical and imaging endpoints with 2-year follow-up
Limitations
- Subgroup effect limited to moderate/severe calcification; no benefit in non/mild calcification
- Open-label procedural guidance differences may introduce performance bias
Future Directions: Define cost-effectiveness and operational pathways for selective OCT use in calcified lesions; evaluate synergy with calcium-modifying therapies (e.g., IVL/atherectomy).
BACKGROUND AND AIMS: The large-scale, randomized ILUMIEN IV trial was examined to determine whether procedural guidance with optical coherence tomography (OCT) during percutaneous coronary intervention (PCI) of angiographically calcified lesions improves outcomes. METHODS: Patients with a single PCI target lesion were included in the present analysis. The presence of none, mild, moderate or severe lesion calcification was determined by an angiographic core laboratory. The primary imaging endpoint was the post-PCI minimal stent area (MSA) assessed by OCT. The primary clinical endpoint was 2-year target-vessel failure (TVF), a composite of cardiac death, target-vessel myocardial infarction (TV-MI), or ischaemia-driven target-vessel revascularization. RESULTS: In the overall population (n = 2114), there was a significant interaction between the effect of randomization to OCT guidance vs angiography guidance in lesions with moderate/severe calcification (n = 1082) vs no/mild calcification (n = 1032) on the 2-year rate of TVF (Pinteraction = .01). The post-PCI MSA in moderately and severely calcified lesions was larger with OCT guidance (n = 544) compared with angiography guidance (n = 538) (5.57 ± 1.86 mm2 vs 5.33 ± 1.78 mm2; P = .03). In the moderate/severe calcified lesion cohort, TVF within 2 years occurred in 35 patients with OCT guidance and in 51 patients with angiography guidance (6.8% vs 9.7%; adjusted hazard ratio [aHR] 0.62; 95% confidence interval [CI] 0.40-0.96), whereas there was no significant difference in TVF in the no/mild calcified lesion cohort (7.7% vs 5.2%; aHR 1.48; 95% CI 0.90-2.44) (Pinteraction = .01). In moderately/severely calcified lesions, OCT-guided PCI also reduced the 2-year rates of serious major adverse cardiac events (2.8% vs 4.7%; aHR 0.49; 95% CI 0.25-0.95; P = .03), TV-MI (1.9% vs 4.0%; aHR 0.36; 95% CI 0.17-0.79; P = .01), and stent thrombosis (0.2% vs 1.5%; aHR 0.11; 95% CI 0.01-0.89; P = .04) compared with angiography-guided PCI. CONCLUSIONS: In the ILUMIEN IV trial, OCT-guided PCI in patients with angiographically determined moderately or severely calcified lesions reduced the 2-year rate of TVF compared with angiography-guided PCI, an effect that was not seen in patients with lesions with no or mild angiographic calcium.
3. Glucagon-Like Peptide-1 Receptor Agonists and Risk of Nontraumatic Intracerebral Hemorrhage in Patients With Type 2 Diabetes.
In a large propensity-matched cohort of patients with type 2 diabetes, GLP-1RA use was associated with a lower risk of nontraumatic intracerebral hemorrhage (HR 0.743), consistent across hemorrhage locations. These findings suggest cerebrovascular safety benefits beyond ischemic stroke reduction.
Impact: The study addresses a key safety question for widely used cardiometabolic agents, suggesting GLP-1RAs may reduce hemorrhagic stroke risk in diabetes—a finding with implications for risk–benefit assessment.
Clinical Implications: For T2D patients at elevated hemorrhagic risk (e.g., hypertension, small vessel disease), GLP-1RAs may offer cerebrovascular safety advantages; however, prospective confirmation is needed before practice changes.
Key Findings
- Propensity-matched cohort size: 255,460 GLP-1RA users vs 255,460 non-users from TriNetX global data.
- GLP-1RA use associated with lower ICH risk (HR 0.743; 95% CI 0.684–0.807).
- The lower ICH risk was observed across intracerebral hemorrhage locations in subgroup analyses.
Methodological Strengths
- Very large real-world dataset with 1:1 propensity score matching
- Assessment across overall and location-specific ICH with up to 4-year follow-up
Limitations
- Observational design subject to residual confounding and coding biases
- Medication exposure misclassification and unmeasured factors cannot be excluded
Future Directions: Prospective randomized or pragmatic trials to confirm hemorrhagic stroke protection and elucidate mechanisms (BP lowering, anti-inflammatory effects) across cerebrovascular phenotypes.
BACKGROUND: GLP-1RAs (glucagon-like peptide-1 receptor agonists) have consistently demonstrated a protective effect against ischemic stroke. However, whether this benefit also extends to nontraumatic intracerebral hemorrhage (ICH) remains unknown. Given the blood pressure-lowering and anti-inflammatory properties of GLP-1RAs, we aimed to evaluate their potential impact on ICH risk in patients with type 2 diabetes. METHODS: We conducted a retrospective cohort study using global health care data from the TriNetX network. Patients with type 2 diabetes who used GLP-1RAs (n=326 777) were compared with those who did not (n=643 614). Propensity score matching (1:1) was performed to balance baseline characteristics, and follow-up was conducted for up to 4 years. The primary outcomes included all-cause mortality, ischemic stroke, and ICH (overall and by location). Hazard ratios and 95% CIs were calculated to assess the mean treatment effect in the treated group. RESULTS: After propensity score matching (resulting in 2 balanced groups of 255 460 individuals each), GLP-1RAs use was associated with a lower risk of ICH (hazard ratio, 0.743 [95% CI, 0.684-0.807]). The lower ICH risk associated with GLP-1RAs was observed across all ICH locations (all CONCLUSIONS: This study highlights a novel potential association between GLP-1RAs and a lower risk of ICH in patients with type 2 diabetes. Prospective studies and future trials are needed to confirm the potential protective effect of GLP-1RAs on small vessel rupture.